Remove and discard the device and apply a new device to a different location on the body.

If the application site becomes irritated or inflamed, remove and discard the device and apply a new device to a different location on the body at least 76mm from the original site. If infection, irritation or inflammation persists or worsens, discontinue use and contact your healthcare professional.

Infection, irritation or inflammation from using i-Port Advance^™ is rare; however, the potential exists. Typically, these occurrences may result from inadequate cleansing of the skin surface before application, improper application to the body, and/or improper maintenance of the insertion site.

Patients should speak with their healthcare provider and refer to the appropriate drug manufacturer's label prior to injecting any medication into i-Port Advance^™.

Do not attempt to reuse an i-Port Advance^™ after the 72 hour wear period has elapsed. Do not attempt to reuse an i-Port Advance^™ after it has been removed or dislodged.

The thickest needle size for use with either i-Port Advance^™ is a 28 gauge needle. Note: The smaller the number, the larger the gauge.

The maximum needle length for use with i-Port Advance^™ is 8mm. Do not attempt to use a 12mm injection needle with i-Port Advance^™. Doing so may damage the device causing unnecessary punctures of the skin, or tearing and puncturing of the soft cannula which may result in unpredictable medication delivery. Do not use a needle shorter than 5mm when injecting in to i-Port Advance^™.

i-Port Advance^™ has a residual volume up to 0.0026 mL.

The cannula is the small soft, flexible tube used to deliver the medication into the subcutaneous tissue. The cannula of i-Port Advance^™ is available in 6mm and 9mm lengths.

i-Port Advance^™ is 38mm in diameter and rises only 8.5mm above the skin.

i-Port Advance^™ is a single use device. Remove and properly dispose of the used device every 72 hours and replace with a new device on a different location of the body as needed.

i-Port Advance^™ is suitable for both adults and children requiring daily subcutaneous injections.

The recommended application sites are illustrated below:

Our recommendation is to speak to your healthcare provider and refer to the drug manufacturer’s label regarding mixing of insulins through a single i-Port Advance^™

Yes, insulin pens may be used with i-Port Advance^™ as long as the needle length does not exceed 8mm or is not shorter than 5mm.

Avoid applying and using a new device just prior to bedtime, unless blood sugar can be checked 1 to 3 hours after injection.

In the case of unexplainably high blood sugar, remove and discard i-Port Advance^™ device and apply new device to a different location on the body, as the cannula could be dislodged, crimped (bent) or partially clogged. Should suggested actions not provide a resolution to the problem or should your blood glucose remain high, contact your physician or healthcare provider.

Test blood sugar per your healthcare professional's instructions to ensure that insulin dose and absorption at the delivery site are appropriate.

The MiniMed™ 770G system, sometimes referred to as a hybrid closed loop system, automatically adjusts* delivery of basal (background) insulin based on CGM readings. This means that the pump gets glucose readings from the Guardian^™ Sensor 3 and transmitter automatically, and then gives you more or less insulin based on your real-time needs. Having a pump and a CGM that speak to one another can help reduce both high and low glucose levels^1,2. *Refers to SmartGuard^™ Auto Mode. Some user interaction required. Individual results may vary. https://www.medtronic-diabetes.com.au/mm780g-supported-devices

The Carelink^™ Connect app allows up to 5 care partners to view pump and CGM data. However, each care partner is only able to view the sugar levels of one pumper through the app. Care partners are still able to login to the CareLink^™ Personal portal online to view data from multiple people, but will have to have separate accounts for each pumper.

The MiniMed^™ 770G system features SmartGuard^™ Auto Mode and compatible smartphone apps. Every 5 minutes, SmartGuard™ Auto Mode automatically determines whether to deliver insulin. If you’re trending high, it will give you more insulin. If you’re trending low, it will give you less insulin until your levels are stabilised.

No, while you can download the app, it will not provide you with any data unless you’re using a MiniMed^™ 770G system. The MiniMed™ Mobile app cannot be used with previous generations of MiniMed^™ insulin pumps or on its own.

Yes. The MiniMed^™ 770G system transmits to your smartphone via wireless Bluetooth^® technology. To see if your smartphone is compatible: https://www.medtronic-diabetes.com.au/mm780g-supported-devices. You are now leaving InterMed Medtronic New Zealand. If you have any questions, please contact our Medtronic Technical Support in New Zealand on 0800 633 487

The MiniMed^™ 770G system is approved for people with Type 1 diabetes age 7 and above. If you would like a CGM and not an insulin pump, consider looking into the Guardian^™Connect CGM.

The low glucose features allow you to set your pump to alert, to suspend insulin, or alert and suspend insulin if you are either approaching your low Sensor Glucose limit, or you have reached your low Sensor Glucose limit.

• Suspend before low: Your pump temporarily stops delivering insulin if it is predicted that your Sensor Glucose reading will be approaching the low limit within 30 minutes. Turning on suspend before low, automatically turns on alert on low.
• Alert before low: Your system alerts you any time it is predicted that your Sensor Glucose reading will reach the low limit within 30 minutes. The alert before low can be used whether suspend before low is turned off or on.
• Suspend on low: Your pump temporarily stops delivering insulin when your sensor glucose value falls to or below the pre-set low limit. Turning on suspend on low, automatically turns on alert on low.
• Alert on low: Your system alerts you when your Sensor Glucose reading reaches or falls below your low limit. This is not an optional alert.

The two-hour period is based on clinical evidence and allows blood glucose to return to normal. The 4-hour period for resuming insulin delivery after halting it reduces the risk of rebound hyperglycaemia.

Low glucose suspend feature^ (when used in conjunction with Continuous Glucose Monitoring (CGM)) is a feature to help if you want additional protection against hypoglycaemia or hypoglycaemia unawareness. If the feature is turned on, the pump automatically suspends insulin infusion for 2 hours when glucose levels reach a pre-determined threshold and, without intervention, will resume basal insulin delivery to its pre-set rate. All other sensor functions remain operational during insulin suspension.

^ Components sold separately.

Weighs just 102 grams including battery.

Measures approximately 5.3 (width) x 9.6 (length) x 2.44 (depth) cm.

If the transmitter and insulin pump are too far apart (about 2 metres or 6 feet), an alert will sound and either a "LOST SENSOR SIGNAL” or “SENSOR SIGNAL NOT FOUND" message will appear on the screen. The transmitter holds 10 hours’ worth of memory and if the transmitter and insulin pump are too far apart for longer than 10 hours, reports may have a "data gap" where information is missing during this time period.

When used continuously, the rechargeable transmitter has a lifespan of approximately 12 months.

A glucose sensor is a tiny electrode that measures your glucose levels. It sits under the skin in your interstitial fluid, where cells get oxygen and nutrients, including glucose. Glucose sensors are easily inserted using an automatic insertion device: like many types of infusion sets, a needle is used to insert the glucose sensor. The needle is then removed leaving just the tiny flexible electrode under the skin. The glucose sensor is then connected either to a transmitter so that readings can be transmitted to your insulin pump or mobile device.

Using glucose sensors does not replace the need for fingerstick measurements. You still need to use your blood glucose meter to confirm a Continuous Glucose Monitoring (CGM) reading before treating or to calibrate the CGM system.

If you have the ‘Sync to CareLink’ setting turned on, you will no longer have to manually upload your data to CareLink. This means that you’ll save time during your office visits because you will not need to download your data while in the office. Furthermore, having more details about your diabetes will allow you to have productive conversations with your healthcare professional about your treatment options.

Within your CareLink^™ Connect tab, you will be able to remove care partner from seeing your data.

Yes, care partners can follow more than one person using Guardian^™ Connect. Care partners will need to have unique logins for each CareLink^™ account in order to follow more than one person. Care partners can also receive SMS messages for more than one person using Guardian^™ Connect. The name of each person will be prominently displayed in the relevant SMS messages.

Medtronic pays for the service of the SMS message to be sent from CareLink^™ to the care partner. Please refer to carrier for information on charges for received SMS messages.

If the transmitter and iOS device are within range and you are in cellular or wireless network, the SMS should be sent within one minute from the time that the alert has triggered from within the app (unless you care partner has set a delay).

When care partners set up their CareLink^™ accounts, they have the ability to specify for which alerts they wish to receive SMS messages. Care partners can also choose to set a delay period between when the alert is triggered in the app and when they receive the SMS message. This delay period was designed to allow the person with diabetes to take action to bring their sensor glucose levels within range before the care partner is notified.

No, care partners do not need to have compatible devices in order to access Guardian^™ Connect data.

You can share your data with up to five people.

To use Guardian^™ Connect, you do need a CareLink^™ account. You do not necessarily have to send your information to CareLink^™ and/or to enroll any care partners, but you do need to have a CareLink^™ account in order to use Guardian^™ Connect. You will be prompted to sign up for a free CareLink^™ account when your first set up Guardian^™ Connect

Whether it's for a day at the beach or because you want to take a 'pump holiday’, you can easily disconnect the pump for up to two hours*. Or you can return temporarily to injections. This can be easier when you establish a plan beforehand. Below are guidelines to help you and your healthcare provider create a plan for you. Note: The guidelines assume that you continue to use your pump insulin - most often fast-acting Humalog^® or NovoRapid^® - but that you are taking it by injection.

_{*As stated in the Medtronic Clinician workshop module 1, Session 3 slide 30 developed by Dr. Mark Forbes.}

 

DISCONNECTING FOR UP TO 1 HOUR:

• Testing: Check blood glucose (BG) before disconnecting.
• Basal insulin: No injections required.
• Exercise: Check BG before, midway and after exercise; monitor closely over the 24 hours following vigorous exercise. Decrease dose(s) (basal and bolus) accordingly.
• Bolus^™ insulin: Take injection (or re-connect/bolus) to cover carbs according to insulin-to-carb ratio and based on BG. Take injection(s) (or re-connect/bolus) to correct high BG using correction formula. If BG >13 mmol/L, check ketones.

DISCONNECTING FOR UP TO 4 HOURS:

• Testing: Monitor blood glucose (BG) before disconnecting, before meals and after the 3rd hour.
• Basal insulin: Take injection equal to missed basal dose.
• Exercise: Check BG before, midway and after exercise; monitor closely over the 24 hours following vigorous exercise. Decrease dose(s) (basal and bolus) accordingly.
• Bolus^™ insulin: Take injection (or reconnect/bolus) to cover carbs according to insulin-to-carb ratio and based on BG. Take injection(s) (or reconnect/bolus) to correct high BG using correction formula. If BG is greater than 13 mmol/L, check ketones.

DISCONNECTING OVERNIGHT:

• Testing: Monitor blood glucose (BG) before sleep and set alarm to test every 3 to 4 hours.
• Basal insulin: Every 4 hours, take injection equal to missed basal dose.
• Exercise: Check BG before, midway and after exercise; monitor closely over the 24 hours following vigorous exercise. Decrease dose(s) (basal and bolus) accordingly.
• Bolus^™ insulin: Take injection (or re-connect/bolus) to cover carbs according to insulin-to-carb ratio and based on blood BG. Take injection(s) (or re-connect/bolus) to correct high BG using correction formula. If BG is greater than 13 mmol/L, check ketones.

DISCONNECTING FOR UP TO 24 HOURS:

• Testing: Check blood glucose (BG) before meals, every 3-4 hours and before sleep.
• Basal insulin: Every 4 hours, take injection equal to missed basal dose.
• Exercise: Check BG before, midway and after exercise; monitor closely over the 24 hours following vigorous exercise. Decrease dose(s) (basal and bolus) accordingly.
• Bolus^™ insulin: Take injection (or re-connect/bolus) to cover carbs according to insulin-to-carb ratio and based on BG. Take injection(s) (or re-connect/bolus) to correct high BG using correction formula. If BG is greater than 13 mmol/L check ketones.

DISCONNECTING FOR MORE THAN 1 DAY:

• Testing: Frequent blood glucose (BG) monitoring is recommended for optimal control.
• Basal insulin: For convenience, your healthcare provider may prescribe longer-acting insulin in place of fast-acting insulin.
• Exercise: Check BG before, midway and after exercise; monitor closely over the 24 hours following vigorous exercise. Decrease dose(s) (basal and bolus) accordingly.
• Bolus^™ insulin: Take injection (or re-connect/bolus) to cover carbs according to insulin-to-carb ratio and based on BG. Take injection(s) (or re-connect/bolus) to correct high BG using correction formula. If BG is greater than13 mmol/L, check ketones.

If you have any questions concerning your care while disconnected from your insulin pump, please contact your healthcare provider. For questions about using Medtronic Diabetes insulin pump features, please contact Medtronic Diabetes.

_{Humalog is a registered trademark of Eli Lilly and Company. NovoRapid is a registered trademark of Novo Nordisk A/S.}

Medtronic does not test reservoirs and infusion sets from other manufacturers and as a result, cannot guarantee their performance with Medtronic MiniMed^® Insulin Pumps. Using non-Medtronic consumables creates a combination not covered by the risk analyses conducted by Medtronic. If any damages result, these will fall outside the terms of its warranty.

Medtronic offers the widest range of infusion sets on the market to meet as many needs as possible. There are many factors that may determine your choice of infusion set, including your age, lifestyle, body type or just individual preference